GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer

Three New Studies Initiated in Other Oncology Settings LONDON and COPENHAGEN, Denmark, Jan. 30 /PRNewswire-USNewswire/ -- GlaxoSmithKline (GSK) and Genmab A/S (OMX: GEN) announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ...

Medarex Announces 2008 Fourth Quarter and Year End Financial Results

...hare, from Medarex's sale of 2.5 million shares of genmab A/S ("Genmab") stock in February 2008; a non-cash ...fair market value of Medarex's equity interests in genmab and Celldex were approximately $87.4 million and a... million through the sale of 2.5 million shares of genmab A/S common stock, reducing our ownership in...

Genmab Announces 2008 First Half Year Results

... Summary: genmab Reports Results for the Six Month Period Ended Jun... COPENHAGEN, August 27 /PRNewswire-FirstCall/ -- genmab A/S (OMX: GEN) announced today results for the six...th period ended June 30, 2008. During this period, genmab reported the following results: Genmab's revenue...

Medarex Announces 2008 First Quarter Financial Results

...hare, from Medarex's sale of 2.5 million shares of genmab A/S stock in February 2008, Medarex's net income f...od in 2007. In addition to the gain on the sale of genmab A/S stock, Medarex's net income for the quarter en... fair market value of Medarex's equity interest in genmab was approximately $115.6 million as of March 31, 2...

QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes

...rp. (Nasdaq: ARTC ) Endo Pharmaceuticals Hldgs. (Nasdaq: ENDP ) Fresenius Medical Care AG (XETRA: FME.DE) GEDEON RICHTER RT (XETRA: R1G1.DE) genmab A/S (Copenhagen: GEN.CO) H. LUNDBECK A/S (Copenhagen: LUN.CO) Human Genome Sciences (Nasdaq: HGSI ) Imclone Systems (Nasdaq: IMCL ) Invernes...

Medarex Announces 2007 Fourth Quarter and Year End Financial Results

...arex's sale of approximately 2.6 million shares of genmab A/S stock in February 2007, Medarex's net loss for... fair market value of Medarex's equity interest in genmab was approximately $291.2 million as of December 31... the sale of approximately 2.6 million shares of genmab A/S common stock. "We enter 2008 with great ...

Genmab Initiates Ofatumumab Phase II Study in Diffuse Large B-Cell Lymphoma

... Summary: genmab has Initiated a Phase II Study of Ofatumumab in Re...EN, Denmark, December 13 /PRNewswire-FirstCall/ -- genmab A/S (OMX: GEN) announced today that study centers ...evelopment and commercialization agreement between genmab and GlaxoSmithKline. "We have now expanded the o...

Genmab and GlaxoSmithKline Initiate Ofatumumab Rheumatoid Arthritis Phase III Program

... Summary: genmab and GSK Have Announced the Initiation of the Phase...EN, Denmark, November 20 /PRNewswire-FirstCall/ -- genmab A/S (OMX: GEN) and GlaxoSmithKline (LSE and NYSE: ... "We are very pleased that our collaboration with genmab has progressed so that we can now move to the next...

Genmab in Medical Technology

Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio

Review Zanolimumab Program to be Discontinued and Headcount to be Reduced Summary: Genmab Announces the Results of its Portfolio Review; Zanolimumab Program to be Discontinued and the Company Will Reduce the Number of Employees COPENHAGEN, October 8 /PRNewswire-F...

Bionomics Achieves US$1 Million Milestone Payment from Genmab

ADELAIDE and COPENHAGEN, Feb. 19 /PRNewswire-FirstCall/ -- Bionomics Limited (ASX: BNO, US OTC: BMICY) today announced the successful completion of pre-clinical testing on the first of eight proteins licensed to US $2.6 billion Danish antibody company Genmab A/S (OMX: GEN), triggering a US $1 ...

New Data on Genmab and GlaxoSmithKline's Ofatumumab: Phase II Study in Rheumatoid Arthritis to be Presented at EULAR

COPENHAGEN, Denmark; April 25, 2007 - Genmab A/S (CSE: GEN) announced today that the results of a Phase II study with ofatumumab (HuMax-CD20™) in patients with rheumatoid arthritis (RA) have been accepted for oral presentation at the 2007 Annual European Congress of Rheumatology (EULAR). The...

GlaxoSmithKline and Genmab Present Positive Phase II Results With ofatumumab in Patients With Rheumatoid Arthritis (RA)

New Data to be Presented at the European League Against Rheumatism (EULAR) Congress Demonstrates the Potential Benefit of ofatumumab in Patients With Rheumatoid Arthritis LONDON, England; PHILADELPHIA, Pennsylvania and COPENHAGEN, Denmark, June 15, 2007 /PRNewswire-FirstCall/ -- GlaxoSmithKline (G...

FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmab's ARZERRA(TM) (ofatumumab)

...wire-FirstCall/ -- GlaxoSmithKline [NYSE: GSK] and genmab A/S [OMX: GEN] today announced that the United Sta...rs of dedicated research and collaboration between genmab and GSK." The advisory committee made its de...b is being developed under a collaboration between genmab and the GSK Oncology and BioPharm R&D Units. ...

Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)

...RNewswire-USNewswire/ -- GlaxoSmithKline (GSK) and genmab A/S (OMX: GEN) announced today positive results fr...ly collaborating on filing submissions." genmab and GSK now expect to file a Biologics License App...evelopment and commercialization agreement between genmab and GlaxoSmithKline. It is not yet approved for an...

Recruitment Completed in Ofatumumab NHL Pivotal Study

... Summary: genmab has Completed Recruitment of Patients in the Phase...COPENHAGEN, September 23 /PRNewswire-FirstCall/ -- genmab A/S (OMX: GEN) announced today it has completed re...evelopment and commercialization agreement between genmab and GlaxoSmithKline. It is not yet approved for sa...

Genmab Announces Upcoming Ofatumumab Studies

...AGEN, Denmark, August 25 /PRNewswire-FirstCall/ -- genmab has announced plans to begin four studies of ofatu...lymphocytic leukemia and non-Hodgkin's lymphoma. genmab A/S (OMX: GEN) announced today plans to begin four...evelopment and commercialization agreement between genmab and GlaxoSmithKline. It is not yet approved in any...

Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study

...nt COPENHAGEN, July 31 /PRNewswire-FirstCall/ -- genmab A/S (OMX: GEN) and GlaxoSmithKline (LSE and NYSE: ...This also represents a significant achievement for genmab as we now move toward filing of the first marketin...t and Medicine Development Leader at GSK. "GSK and genmab are collaborating on a comprehensive development p...

Genmab A/S - Company Announcement: Recruitment Completed In Ofatumumab CLL Front Line Study

...ne and cyclophosphamide to treat front line CLL. genmab A/S (OMX: GEN) announced today it has completed re...evelopment and commercialization agreement between genmab and GlaxoSmithKline. It is not yet approved in any...d at any time during the treatment period. About genmab A/S ...

Genmab in Biological Technology

Passing of Genmab A/S' Annual General Meeting

COPENHAGEN, April 23 /PRNewswire-FirstCall/ -- Summary: At Genmab A/S' Annual General Meeting held today on April 23, 2008 the Annual Report for 2007 was approved, discharge was given to the Board of Directors and the Management and the year's loss was carried forward. Two members of the Board...

Medarex Announces Completion of Sale of Shares in Genmab A/S

PRINCETON, N.J., Feb. 1 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX ) announced today that it has completed the sale of approximately 2.5 million shares of Genmab A/S which stock is traded on the Copenhagen Stock Exchange. The trade is expected to settle on February 1, 2008. Medarex...

Roche Files IND for Second Genmab Antibody

Summary: Genmab's Partner Roche has Filed an IND With the US FDA for a Genmab Antibody COPENHAGEN, August 10 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today that its partner Roche has filed an Investigational New Drug application (IND) with the US Fo...

Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic

Summary: An IND has Been Filed With the FDA for the Fourth Genmab Antibody Developed Under the Company's Collaboration with Roche. COPENHAGEN, December 12 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today that an Investigational New Drug application (IND) for a Genmab antib...

Pepscan Achieves First Milestone in Research Collaboration With Genmab

LELYSTAD, The Netherlands, March 10 /PRNewswire/ -- Pepscan Therapeutics (Pepscan) today announced that it has earned a milestone payment from Genmab A/S. The milestone payment arises from an ongoing Research Collaboration aimed at identifying human antibodies against intractable targets. Peps...

Life Science Leaders Discuss Strategies for Surviving the Financial Crisis at Yankee Public Relations Symposium

...e more reticent. They are looking at a completely different risk-reward equation." Symposium panelists also included: Annarie Lyles , Ph.D., genmab , Senior Vice President/Head of Business Development; Andrew Reaume , Ph.D., M.B.A., Melior Discovery , President/CEO; Evan Myrianthopoulos ...

Medarex Announces 2009 First Quarter Financial Results

... per share, from the sale of 2.5 million shares of genmab A/S stock in February 2008. Medarex's net loss for...fair market value of Medarex's equity interests in genmab and Celldex Therapeutics were approximately $85.3 ...4,490 67,154 Marketable securities - genmab 85,274 87,428 Inve...

Ernst & Young Benchmarks Danish Biotech Pipeline Third in Europe

...stronger" prepared in cooperation with the Danish Association of Biotechnology Industries. "Being a global biotech company founded in Denmark, genmab is proud to be part of the important Medicon Valley biotech sector. We have found the innovative climate inspiring in the process of building our late...

Genmab A/S: Ofatumumab Pivotal CLL Data to be Presented at ASH

... COPENHAGEN, November 10 /PRNewswire-FirstCall/ -- genmab A/S (OMX: GEN) announced today that three ofatumum...evelopment and commercialization agreement between genmab and GlaxoSmithKline. It is not yet approved for sale in any country. About genmab A/S ...

Medarex Announces 2008 Third Quarter Financial Results

...fair market value of Medarex's equity interests in genmab A/S and Celldex Therapeutics, Inc. were approximat... - 14,000 Marketable securities - genmab - 152,000 Other c... 72,127 79,925 Marketable securities - genmab non-current 131,704 139,165 Investm...